CorVista Health Welcomes New Member to its Executive Management Team

CorVista Health has gained two top managers: The company recently appointed Nikki Troiano Gainey as chief customer officer and Ian Shadforth as chief strategy officer.

Gainey will lead CorVista’s customer strategy, commercial execution, and market development, as the company expands adoption of the CorVista System, a non-invasive, point-of-care platform designed to support cardiovascular disease detection and clinical decision-making. Shadforth will focus on enterprise strategy, strategic partnerships, and long-term growth initiatives.

The appointments coincide with CorVista’s efforts to advance the commercialization of its artificial intelligence (AI)-enabled, non-invasive cardiovascular testing platform. The CorVista System uses machine-learned algorithms to analyze cardiac signals and support the detection of multiple cardiovascular conditions at the initial point of care—guiding the physician to make faster, well-informed care decisions.

“Nikki brings a rare combination of global medtech leadership, enterprise strategy, commercialization expertise, and deep cardiovascular and imaging experience,” CorVista Health President/CEO Adrian Lam said. “Her track record of scaling complex technologies, building strategic partnerships, and aligning commercial execution with enterprise value creation makes her exceptionally well suited to lead our customer organization at this important stage of growth.”

Gainey has more than 25 years of global medical device leadership experience across cardiovascular and advanced imaging technologies, commercialization, and go-to-market strategy. She has held senior leadership roles at Siemens Healthcare and GE Healthcare. Most recently, Gainey was CEO of Trivirum and chief commercial and strategy officer at YorLabs. Gainey also serves as a board advisor for numerous other organizations.

Gainey earned an MBA from North Carolina State University, with a focus on technology commercialization and innovation, and a bachelor’s degree from Ohio Northern University.

“I am honored to join CorVista at such a pivotal moment,” Gainey stated. “CorVista has the opportunity to change how cardiovascular disease is detected and managed by bringing powerful, non-invasive diagnostic technology into the point of care. I look forward to working with the team, our customers, and our partners to expand access, accelerate adoption, and support clinicians in delivering earlier answers for patients.”

Shadforth originally joined Analytics for Life, CorVista’s parent company, in 2015 and has since served in multiple strategic roles, most recently as vice president and general manager of CorVista Health. He brings extensive experience in the science, strategy, and development of connected health ecosystems.

“Ian has played a critical role in shaping CorVista’s commercial foundation and market approach,” Lam commented. “As chief strategy officer, he will help guide the company’s next phase of growth, including strategic partnerships, real-world evidence generation, and corporate development priorities. We are grateful for his leadership and excited to have him focused on the strategic opportunities ahead.”

Before joining Analytics for Life, Shadforth pioneered programs at both Johnson & Johnson and GlaxoSmithKline and served as co-founder/CEO of AffirmXH Inc. Shadforth earned a doctorate in bioinformatics from Cranfield University and an MBA from the University of Dundee. He holds numerous patents in machine learning, diagnostics, and disease management, and is co-author of “Building Bioinformatics Solutions” (Oxford University Press).

“CorVista has built something genuinely differentiated—a non-invasive platform with the potential to fundamentally change how cardiovascular disease is detected and managed at the point of care,” Shadforth stated. “I’m excited to step into this strategic role at a time when the opportunity to expand our partnerships, advance real-world evidence, and drive long-term growth has never been clearer.”

CorVista Health is dedicated to transforming cardiovascular care through diagnostics that shorten the path from symptoms to diagnosis. By enabling earlier detection of complex cardiovascular conditions, CorVista aims to empower clinicians with actionable insights and improve patient outcomes across diverse care settings.